Abstract

Fibronectin has been shown to bind to integrin alphaIIbbeta3 in Arg-Gly-Asp (RGD)-dependent and -independent manners. A recent study has indicated that a 29-kDa dispase-digestive fragment from the C-terminal heparin-binding domain of human plasma fibronectin (lacking RGD sequence) inhibits binding of fibronectin to thrombin-stimulated platelets and ADP-induced aggregation (Tanabe, J. , Fujita, H., Iwamatsu, A., Mohri, H., and Ohkubo, T.(1993) J. Biol. Chem. 268, 27143-27147). We provide here the evidence that a peptide corresponding to residues from Ala1704 to Glu1718 (designated F1) from this fragment inhibited binding of 125I-labeled 29-kDa fragment of fibronectin to thrombin-stimulated platelets and ADP-induced aggregation. The F1 peptide bound directly to alphaIIbbeta3 integrin receptor. These results indicate that a novel binding site in the C-terminal heparin-binding region of fibronectin is localized within the residues from Ala1704 to Glu1718. Binding of 125I-labeled 29-kDa fragment of fibronectin to thrombin-stimulated platelets was not inhibited by RGDS peptide and the 12-residue peptide from the cell-binding domain of fibronectin, suggesting that binding site in the C-terminal heparin-binding domain may be different from those of RGDS and the 12-residue peptide. This additional alphaIIbbeta3-binding domain(s) in fibronectin may also play some role for prevention of thrombus formation by direct interaction with alphaIIbbeta3.

Highlights

  • RGD-containing peptides block binding of fibronectin to unstimulated platelets [13]

  • We have studied the interaction of synthetic peptides derived from the C-terminal heparin-binding domain of fibronectin with integrin receptor ␣IIb␤3

  • There are three key findings: (a) an active binding site of the C-terminal heparinbinding domain of fibronectin that inhibited binding of the 29-kDa fragment to ␣IIb␤3 was a sequence corresponding to the residues from Ala1704 to Glu1718; (b) a peptide including this binding site inhibited both bindings of fibronectin and fibrinogen to ␣IIb␤3 in a dose-dependent manner; (c) a binding site of this peptide on ␣IIb␤3 may be different from that of RGDS and of the 12-residue peptide in the cell-binding domain of fibronectin

Read more

Summary

Plasma Fibronectin*

(Received for publication, November 29, 1995, and in revised form, March 11, 1996). From The First Department of Internal Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236, Japan. The F1 peptide bound directly to ␣IIb␤3 integrin receptor These results indicate that a novel binding site in the C-terminal heparin-binding region of fibronectin is localized within the residues from Ala1704 to Glu1718. One site is located in the N-terminal region of the cellbinding domain of fibronectin corresponding to the residues from Ile1359 to Ser1436 This recombinant fragment of fibronectin inhibited binding of fibronectin to ␣IIb␤3 and ADP-induced platelet aggregation [14]. Responding to residues from Ala1597 to Glu1963 [15] This fragment lacks RGD sequence, inhibits binding of fibronectin to thrombin-stimulated platelets as well as heparin and ADPinduced platelet aggregation and binds to immobilized ␣IIb␤3. These results suggest that three different binding sites in fi-. The binding site of this peptide on ␣IIb␤3 might be different from those of RGDS and the sequence in the N-terminal region of cell-binding domain of fi-

EXPERIMENTAL PROCEDURE
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call